NEW YORK (GenomeWeb News) — Shares in Decode Genetics were down 14.19 percent, or $.82, at $5.02 in mid-afternoon trading after the company said it was forced to halt the study of a heart drug.
 
Decode said it suspended the Pjhase III trial of its heart attack drug DG031 after discovering that tablets appear to dissolve more slowly over time than had been originally believed.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.